In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Madrigal Pharmaceuticals (MDGL), with a price target of $120.00. The company’s shares closed last Monday at $84.52, close to its 52-week low of $74.05.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 5.4% and a 44.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Pacira Pharmaceuticals, and Rhythm Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Madrigal Pharmaceuticals with a $171.00 average price target.
See today’s analyst top recommended stocks >>
Based on Madrigal Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $27.74 million. In comparison, last year the company had a GAAP net loss of $11.48 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia.
Read More on MDGL: